Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2026-05-25 Remuneration Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Change to CEO remuneration 3 pages 192.7KB
Remuneration Information Classification · 98% confidence The document is an ASX announcement detailing the revised remuneration package for the CEO, including fixed pay, STI and LTI targets. It does not announce a management change but specifically outlines compensation terms for a top executive. This matches the Remuneration Information category (Code: DEF 14A).
2026-05-25 English
2026 Q2 Investor Webinar Presentation 19 pages 1.2MB
Investor Presentation Classification · 93% confidence The document is a slide deck titled “2026 Q2 Investor Webinar” with detailed corporate strategy, pipeline updates, and forward-looking statements, intended for investors rather than serving as a formal financial filing or annual report. It is clearly an investor presentation.
2026-05-21 English
Ceasing to be a substantial holder 5 pages 294.3KB
Major Shareholding Notification Classification · 90% confidence The document is an Australian Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001, detailing changes in relevant interests and thresholds of share ownership by Firetrail Investments Pty Ltd. It is a regulatory notification of crossing significant shareholding thresholds, not a financial report or meeting material. This falls under Major Shareholding Notification (Code: MRQ).
2026-05-17 English
Investor Webinar 2 pages 458.5KB
Regulatory Filings Classification · 85% confidence The document is an announcement of an upcoming investor webinar date/time and registration details. It contains no substantive financial data, no presentation slides, no report attached, and is clearly a regulatory announcement for ASX compliance rather than the report or presentation itself. This falls under the generic “Regulatory Filings” category as a miscellaneous announcement.
2026-05-11 English
Notification of cessation of securities - PYC 9 pages 25.5KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 3H announcement notifying the cessation (lapse or expiry) of unquoted equity securities (options) and summarizing the changes to issued capital. It is not reporting financial results, legal proceedings, or dividend information. Instead, it details a corporate capital change affecting share classes. Therefore, it falls under the Share Issue/Capital Change category.
2026-05-10 English
PKD - Initiation of Multiple Dose Clinical Trial 3 pages 303.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 7 May 2026 from PYC Therapeutics regarding the initiation of a Phase 1b Multiple Ascending Dose clinical trial for their drug candidate PYC-003 targeting Polycystic Kidney Disease. It provides details about the clinical trial objectives, study design, and expected future data presentations. The document is a press release style announcement about clinical trial progress and future plans, not a financial report, regulatory filing, or detailed investor presentation. It does not contain financial statements, management discussion, or regulatory certifications. It is also not a report publication announcement since it does not mention the release of a report but rather announces a clinical trial milestone. The content fits best under a general regulatory announcement or company update category. Given the available categories, the closest fit is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2026-05-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.